Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Which dose of calcium dobesilate is more effective and safe in chronic venous insufficiency? Multicenter retrospective clinical trial.
Phlebology
September 2024
Department of Cardiovascular Surgery, Memorial Hospital, Ankara, Turkey.
Article Synopsis
- The study evaluated the effectiveness and safety of two dosages of calcium dobesilate (500 mg vs. 1000 mg) in patients with Chronic Venous Insufficiency (CVI) in CEAP classes C3-C4.
- A multicenter retrospective analysis monitored patient progress over 12 months, using scores and circumference measurements to gauge improvement.
- Results showed that the higher dosage (1000 mg) significantly improved symptom relief and reduced limb swelling compared to the lower dosage, indicating a potential benefit of using higher doses for managing advanced CVI.
Assessment of the Tolerance of Dobenox Forte in Patients with Chronic Venous Disease.
Life (Basel)
March 2024
Department of Physiotherapy, School of Health Sciences in Katowice, Medical University of Silesia in Katowice, 40-752 Katowice, Poland.
This prospective, observational, multicenter study assessed the tolerance of Dobenox Forte, the first approved over-the-counter product containing calcium dobesilate, in 1795 outpatients with chronic venous disease (CVD) in daily clinical practice. In addition, the effectiveness (decrease in circumferences of a more affected limb at the ankle and middle part of the calf, and changes in the severity of CVD signs) was assessed. No adverse events related to use of the preparation were reported in a period of 64 ± 20 days.
View Article and Find Full Text PDFClinical application of calcium dobesilate in acute and sub-acute COVID-19: Two case reports.
SAGE Open Med Case Rep
March 2024
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, State of Mexico.
The pathophysiology of the virus causing coronavirus disease 2019, the cytokine storm and severe vasculitis is well known. Diabetic patients and those with microcirculation issues are at risk of complications when diagnosed with coronavirus disease 2019. Calcium dobesilate has been used extensively for microangiopathy, diabetic retinopathy, chronic venous insufficiency, hemorrhoidal and post-thrombotic syndromes.
View Article and Find Full Text PDFCalcium dobesilate-induced hyperpyrexia: A case report.
Medicine (Baltimore)
October 2023
Department of Emergency, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China, 650032.
Rationale: Calcium dobesilate, a vasoprotective and antioxidant agent, is gradually being used for the treatment of chronic kidney disease. Calcium dobesilate-induced hyperpyrexia is a rare clinical event, and few studies have reported it.
Patient Concerns: The patient took calcium dobesilate, which caused high fever.
A nationwide study of compliance of venoactive drugs in chronic venous disease patients.
Ann Surg Treat Res
May 2023
Department of Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
Purpose: Venoactive drugs are widely used to improve the symptoms and signs of chronic venous disease. This study aimed to analyze the rate of adverse events after venoactive drug prescription and subsequent compliance and switching rates.
Methods: Using the National Health Insurance Service database, individuals with at least one chronic venous disease code between January 2009 and December 2019 were identified, and 30% (2,216,780 individuals) of these were sampled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!